EXOZ
eXoZymes, Inc.
There isn't enough reported data to score EXOZ yet.
EXOZ Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
EXOZ's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
EXOZ PE Valuation
EXOZ has no meaningful PE right now: it lost money over the past year.
EXOZ Forward outlook
There aren't enough analyst estimates for EXOZ to show an outlook.
EXOZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$0.70 | -$0.54 |
EXOZ lost $1.20 per share over the past year, and its loss has widened in each of the last seven quarters.
EXOZ Quarterly Revenue
EXOZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.6M | -$51.7K |
| Q1 2026 | -$1.6M | -$417.5K |
| Q4 2025 | -$2M | +$3.9M |
| Q2 2025 | -$1.6M | +$986.5K |
| Q1 2025 | -$1.2M | -980% |
| Q4 2024 | -$5.9M | -$5M |
| Q2 2024 | -$2.6M | -$2.4M |
| Q1 2024 | $132.4K | +$404.3K |
EXOZ has burned cash in almost every quarter: −$7M over the past year, against −$11M the year before.
EXOZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.4% | +201K shares |
| 1 year | +3.4% | +283K shares |
| 3 years | +6.6% | +533K shares |
EXOZ has 9M diluted shares, up 3.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
EXOZ Net Leverage
EXOZ's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
EXOZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.7 | Neutral |
| Stochastic | 19.6 | Oversold |
EXOZ's weekly RSI is 34 (neutral) and its Stochastic is 20 (oversold).
EXOZ PE vs Healthcare Sector
EXOZ has no meaningful PE right now: it lost money over the past year.
EXOZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.74 | 16% below |
| 20 week MA | $5.68 | 30% below |
| 50 week MA | $8.20 | 51% below |
| 100 week MA | $10.6 | 62% below |
EXOZ is in a downtrend: it's below all four of its weekly moving averages, and 62% below its 100-week average.
EXOZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $11.1 | $20.1 | +81% |
| 2025 | $20.1 | $11.5 | -43% |
| 2026 YTD | $11.5 | $4.00 | -65% |
EXOZ has finished lower in one of the last two years. It's down 65% so far in 2026.